0 Kommentare
0 Anteile
3133 Ansichten
Verzeichnis
Descubre gente nueva, crea nuevas conexiones y haz nuevos amigos.
- Please log in to like, share and comment!
- How CROs and Biotech Firms Use Pomalidomide Derivatives for Rapid PROTAC ScreeningContract research organizations and boutique biotech groups have developed pomalidomide derivatives into the most widely used plug-and-play CRBN recruiters: the scaffold provides a clean departure point, gram-scale commercial availability and a largely 'greyed' intellectual-property landscape. Stocking a freezer full of pre-functionalized C4- and C5-linker congeners (acetamides,...0 Kommentare 0 Anteile 3788 Ansichten
- How are Liposomes Different from Micelles?What are Liposomes? Liposome is an artificial carrier membrane. In the water, the hydrophilic head of the phospholipid molecule is inserted into the water, and the hydrophobic tail of the liposome extends to the air, and after agitation, a spherical liposome of bilayer lipid molecules is formed. This bilayer structure is the same as the skin cell membrane structure, which helps the skin to...0 Kommentare 0 Anteile 3541 Ansichten
- The Development Process of DUBTACThe use of Proteolysis Targeting Chimeras (PROTACs) to degrade dysfunctional proteins has shown great potential to target proteins that were previously considered "undruggable", and several projects have entered clinical evaluation worldwide. Aberrant protein degradation, in fact, is also a pathogenic mechanism in some diseases, such as cystic fibrosis (CF) and some forms of cancer....0 Kommentare 0 Anteile 3329 Ansichten
- Unlocking the Future of Gene Therapy: From circRNA Detection to AAV Vector DesignIn recent years, gene therapy has emerged as one of the most promising frontiers in modern medicine. By addressing diseases at their genetic roots, researchers are opening doors to treatments that were once unimaginable. Two areas of innovation—circular RNA (circRNA) detection and AAV vector design for cystic fibrosis—highlight how advanced technologies are reshaping biomedical...0 Kommentare 0 Anteile 3041 Ansichten
- Unlocking the Future of Flow Cytometry with MicrofluidicsFlow cytometry has long been a cornerstone of biomedical research, enabling scientists to analyze thousands of cells in real time. From immune profiling to drug discovery, it provides a window into cellular diversity and function. Yet, as powerful as traditional cytometers are, they can be bulky, resource-intensive, and limited in flexibility. Enter microfluidics—a field that is quietly...0 Kommentare 0 Anteile 3141 Ansichten
- 0 Kommentare 0 Anteile 656 Ansichten
- Dribbling into Delight: Exploring the Fun of Store Management (and Why it Reminds Me of Basket Random)Okay, so store management games. They might not sound like the most adrenaline-pumping genre at first blush. But trust me, when done right, they can be incredibly engaging, offering a satisfying blend of strategy, resource management, and a dash of unpredictable chaos. You’re balancing budgets, keeping customers happy, and trying to turn a profit. It’s a surprisingly addictive...0 Kommentare 0 Anteile 3638 Ansichten
- Complement Assays: Small Experiments, Big QuestionsWalk into any immunology lab today and you'll likely find researchers puzzling over the complement system. It's ancient, powerful, and sometimes unpredictable. For decades, scientists have known that complement proteins can protect us from infection—but they can also drive inflammation and autoimmune disease. The real challenge now is not just understanding what complement does, but how...0 Kommentare 0 Anteile 3266 Ansichten
- Beyond Traditional Models: A New Era of Precision Tools for Neurodrug DevelopmentFor patients living with neurological disorders—stroke, traumatic brain injury, or spinal cord damage—the wait for effective therapies can feel endless. The reality is that developing a new drug can take more than a decade, with countless candidates failing along the way. Researchers are increasingly asking: how can we accelerate this process without compromising safety or...0 Kommentare 0 Anteile 3822 Ansichten